Anat Ashkenazi is recorded as CFO at Alphabet Inc. (GOOGL). Earlier roles on record: CFO at ELI LILLY & Co (LLY) until July 10, 2024 and Board Member at Maravai Lifesciences Holdings, Inc. (MRVI) until July 31, 2024. ELI LILLY & Co reported in an 8-K filed July 10, 2024 that Anat Ashkenazi resigned as executive vice president and chief financial officer. Maravai Lifesciences Holdings, Inc. reported in an 8-K filed June 12, 2024 that Anat Ashkenazi resigned as director, effective July 31, 2024. Alphabet Inc. reported in an 8-K filed June 7, 2024 that Anat Ashkenazi was appointed Chief Financial Officer and Senior Vice President of Alphabet and Google LLC, effective July 31, 2024. Equibles holds 4 filed executive changes naming Anat Ashkenazi; each is listed under recent activity with its source filing. The proxy statement of Alphabet Inc. reports total compensation of $31,259,031 for Anat Ashkenazi in fiscal 2025, including a base salary of $1,003,846. Disclosed compensation is on record for 5 fiscal years. Anat Ashkenazi has spoken on 20 earnings calls and 2 other investor events across 2 companies, most recently for Alphabet Inc. on October 28, 2026. Those appearances were for ELI LILLY & Co (LLY) and Alphabet Inc. (GOOGL). Alphabet Inc. is classified in the Internet Content & Information industry within the Communication Services sector. Other companies whose calls Anat Ashkenazi spoke on are classified in the Healthcare sector. Other leadership on record at Alphabet Inc. includes Sundar Pichai (CEO and Board Member), Ruth M. Porat (CFO), Prabhakar Raghavan (CTO) and 7 others.
“On June 5, 2024, Eli Lilly and Company (the "Company") announced that Anat Ashkenazi resigned as executive vice president and chief financial officer of the Company to pursue another career opportunity outside of the pharmaceutical industry.”
ELI LILLY & Co Form 8-K, filed July 10, 2024
· Read the filing
“On June 10, 2024, Anat Ashkenazi, a director of Maravai LifeSciences Holdings, Inc. (the “Company”), informed the Board of Directors of the Company (the “Board”) that she plans to resign from the Board effective as of July 31, 2024, in consideration of the time commitments associated with her pending appointment as Chief Financial Officer of Alphabet Inc.”
Maravai Lifesciences Holdings, Inc. Form 8-K, filed June 12, 2024
· Read the filing
Anat Ashkenazi on recent calls
“My comments will focus on year-over-year comparisons for the third quarter unless I state otherwise. I will start with the results at the alphabet level and will We'll then cover our segment results.”
“My comments will focus on year-over-year comparisons for the second quarter, unless I state otherwise. I will start with results at the alphabet level and will then cover our segment's result.”
“My comments will focus on year-over-year comparisons for the first quarter unless I state otherwise. I will start with results at the alphabet level and will then cover our segment results.”
